id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-307000-mc5tpnbj	Montero‐Vilchez, T	Management of patients with Hidradenitis Suppurativa during the COVID‐19 pandemic	2020-06-19		.txt	text/plain	667	49	49	Adults and children with HS are at higher risk of cutaneous, extracutaneous and systemic infections, at even higher rates than in patients with psoriasis and atopic dermatitis, which leads to increased mortality 3 . In the most severe COVID-19 cases, the infection is probably associated with a cytokine storm, which is characterized by increased This article is protected by copyright. Although there are no reports on HS treatment during the COVID-19 pandemic or a previous coronavirus epidemic, the guidelines do not recommend stopping treatment due to potential infection risks in the community. Therefore, while there is no evidence that biologics increase the risk or morbidity of a COVID-19 infection, we should not recommend preventively discontinuing these medications. Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations Should patients stop their biologic treatment during the COVID-19 pandemic	./cache/cord-307000-mc5tpnbj.txt	./txt/cord-307000-mc5tpnbj.txt